Treatment of CLL: Evolving Options for BTK Inhibitors
This webinar discusses the evolving options for BTK inhibitors in Chronic Lymphocytic Leukemia (CLL) based on a transcript of a medical discussion. The conversation revolves around two patient cases and provides insights into the treatment decision-making process....Cancer Rehabilitation: Lymphedema
Dr. Mixon begins by defining lymphedema as a chronic, progressive condition often resulting from cancer treatment. A key focus is on identifying patients at high risk, including those undergoing lymph node dissection or radiation. She underscores the importance of risk stratification and proactive intervention to prevent progression to irreversible stages.
Thanks for Confirming Your Email Preferences
Email Confirmation Name First Last Email Email Preferences Yes, I'll Subscribe Please unsubscribe my email...Home-Based Medical Care in Cancer Patients
Dr. Yao highlights that approximately 2 million older adults in the US are permanently homebound, with cancer among the leading diagnoses, and many more experience frequent periods of functional decline or immobility. These patients face significant disparities in access to care, particularly racial and ethnic minorities who are more likely to die at home without adequate support.
Germline Predisposition to Hematopoietic Malignancies
Dr. Godley emphasizes the increasing recognition of germline predisposition in hematopoietic malignancies, challenging traditional assumptions that these genetic factors are rare. The talk includes a short Q&A discussion at the end.
Breast Metastases in Breast Cancer & NCI Women’s Malignancies Branch Clinical Trials
Dr. Zimmer provides an in-depth exploration of brain metastases in breast cancer, emphasizing the challenges in management and evolving treatment strategies, outlining the clinical complexities associated with HER2-positive, triple-negative, and hormone receptor-positive breast cancers and their distinct metastatic patterns and treatment responses.
Blood and Marrow Transplantation Reviews: Optimal Use of Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin’s Lymphoma
The goal of this educational program is to improve the treatment of patients with multiple myeloma (MM) and non-hodgkin lymphoma (NHL) through the dissemination of information about stem cell transplantation and mobilization for autologous hematopoietic cell transplantation. The data for stem cell transplantation in MM is rapidly changing. The techniques of mobilization are still evolving.
Optimal Use of Autologous Transplantation and Stem Cell Mobilization in Patients
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Speakers Parameswaran Hari, MD, MRCP, MS Armand Quick-William Stapp Professor of Hematology Interim Chief Hematology and Oncology Medical...BloodLine Presents: Updates on Current Treatment Options for Cytomegalovirus (CMV) in the Transplant Setting
Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.